| ID | 1140 |
| Name of the vaccine | Prevnar 13 |
| Microbe | Bacteria |
| Disease name | Pneumococcal |
| Name of bacteria | Streptococcus pneumoniae |
| Type of vaccine | Inactivated |
| Nucleic acid content | DNA |
| Age | 6 weeks and older |
| Description of the vaccine | Pneumococcal 13-valent conjugate vaccine (PCV13 ) [Diphtheria CRM197 Protein]. |
| Name of the manufacturer | Pfizer |
| Name of the manufacturing country | Philadelphia |
| Year of manufacture | 2010 |
| Clinical Phase status | Approved |
| Bacterial strain | Gram-positive, facultative anaerobic bacteria. |
| Efficacy | 93.9% in the intent-to-treat analysis. |
| Vaccine formulation | Suspension for injection |
| Dosage | Children (6 weeks to 5 years) : The four-dose series of 0.5 mL administered at 2, 4, 6, and 12-15 months.
Children (6 to 17 years ) and adults: a single dose. |
| Mechanism of action | T-cell dependent immune response. |
| Route of administration | Intramuscular |
| Indications | Prevention of invasive disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F. |
| Export | NA |
| Approval | US FDA |
| Adjuvant | Aluminium phosphate |
| Repurposing | NA |
| Side effects of vaccine | Infants, toddlers and children : irritability, injection site reactions, decreased appetite and sleep, increased sleep, fever.
Adults (18 years and older) : injection site reactions, fatigue, headache, muscle and joint pain, decreased appetite, limitation of arm movement, vomiting, fever, chills and rash.
|
| Post vaccination | NA |
| Dose type | Both |
| Interspecies transfer | NA |
| PubMed identifier | NA |
| Clinical trial number | NA |
| Reference | https://www.fda.gov/media/107657/download |
| Other name | NA |
| Additional Links | NA
|